Login to Your Account



NewCo News: Genentech Colleagues Reunite to Bring Eye Drug to Market

By Marie Powers


Wednesday, December 29, 2010
Launched in 2006 with a $37 million Series A financing by venture capital firms Alta Partners and Clarus Ventures, SARcode Corp. had been working quietly to bring to market a class of small-molecule lymphocyte function-associated antigen-1 (LFA-1) antagonists as a nonsteroidal anti-inflammatory topical agent to treat unmet medical needs in ophthalmology, dermatology and other inflammatory diseases.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription